Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
Subscribe To Our Newsletter & Stay Updated
